Status: Recruiting
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
The purpose of this phase I study is to determine whether MDC-CAR-BCMA001 (BCMA directed CAR T-cells) is safe and tolerable in the treatment of relapsed and refractory B-cell malignancies
Participants needed: 16
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Technische Universität DresdenUpdated: Aug 24, 2025Locations: 1
Eligibility criteria
Male or female patients aged ≥ 18 years [+18]
Any Central nervous system (CNS)-involvement by underlying disease [+29]